Drug evaluation: tagatose in the treatment of type 2 diabetes and obesity.

Moore MC
Curr Opin Investig Drugs. 2006 7 (10): 924-35

PMID: 17086938

Spherix Inc (formerly Biospherics) is developing tagatose, an orally active lactose derivative for the potential treatment of obesity and type 2 diabetes. The compound is also under investigation for the potential treatment of anemia, hemophilia and medical problems related to infertility, birth weight and excessive maternal food intake. Phase I and II clinical trials have been completed.

MeSH Terms (11)

Animals Anti-Obesity Agents Clinical Trials, Phase I as Topic Clinical Trials, Phase II as Topic Contraindications Diabetes Mellitus, Type 2 Hexoses Humans Hypoglycemic Agents Obesity Structure-Activity Relationship

Connections (1)

This publication is referenced by other Labnodes entities: